within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH07_Evogliptin;

model Evogliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BH07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BH07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus. It works by increasing incretin levels, which inhibit glucagon release, increase insulin secretion, and decrease gastric emptying. Evogliptin is approved for use in some countries, including South Korea and Brazil.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Kim, B, et al., &amp; Kim, YC (2023). Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin. <i>Diabetes, obesity &amp; metabolism</i> 25(6) 1769–1776. DOI:<a href=&quot;https://doi.org/10.1111/dom.15034&quot;>10.1111/dom.15034</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36852751/&quot;>https://pubmed.ncbi.nlm.nih.gov/36852751</a></p></li><li><p>Rhee, SJ, et al., &amp; Yu, KS (2016). Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. <i>Drug design, development and therapy</i> 10 1411–1418. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S102459&quot;>10.2147/DDDT.S102459</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27110098/&quot;>https://pubmed.ncbi.nlm.nih.gov/27110098</a></p></li><li><p>Gu, N, et al., &amp; Yu, KS (2014). Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. <i>Drug design, development and therapy</i> 8 1709–1721. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S65678&quot;>10.2147/DDDT.S65678</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25336915/&quot;>https://pubmed.ncbi.nlm.nih.gov/25336915</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Evogliptin;
